Q3 2025 ACADIA Pharmaceuticals Inc Earnings Call Transcript
Key Points
- ACADIA Pharmaceuticals Inc (ACAD) reported total revenues of $278.6 million for the third quarter, marking an 11% increase from the previous year.
- DAYBUE achieved its highest net sales in a single quarter at $101.1 million, with over 1,000 unique patients globally receiving the treatment.
- NUPLAZID delivered record net sales of $177.5 million, representing a 12% year-over-year growth driven by a 9% increase in volume.
- The company initiated a Phase 2 study for ACP-204 in Lewy Body Dementia Psychosis and a Phase 3 study of trofinetide in Japan, indicating strong pipeline progress.
- ACADIA Pharmaceuticals Inc (ACAD) ended the quarter with $847 million in cash, up from $762 million at the end of the second quarter, showcasing strong financial health.
- Despite progress, DAYBUE's market penetration remains relatively low at about 40% in the US and only 27% in the community setting.
- Penetration among patients older than 11 years is significantly lower, indicating a potential challenge in expanding the treatment's reach.
- The company faces increased R&D expenses, which rose to $87.8 million in the third quarter, primarily due to higher clinical trial expenses.
- ACADIA Pharmaceuticals Inc (ACAD) had a disappointing outcome in their Prader-Willi syndrome study, which did not meet expectations.
- The company is making significant investments in expanding its field force, which could increase operational costs and impact short-term profitability.
Good day, ladies and gentlemen, and thank you for standing by. Welcome to ACADIA Pharmaceuticals' third-quarter 2025 financial results conference call. (Operator Instructions)
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications at ACADIA. Please go ahead.
Good afternoon and thank you for joining us on today's call to discuss ACADIA's third-quarter 2025 financial results. Joining me on the call today from ACADIA are Catherine Owen Adams, our Chief Executive Officer who will provide some opening remarks; followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brand, DAYBUE and NUPLAZID. Also joining us today is Elizabeth Thompson, PhD, Executive Vice President, Head of Research and Development, who will provide an update on our pipeline programs; and Mark
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
